About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Speaker: Dr. Jose Antonio Seoane Fernández, coordinates the Cancer Computational Biology group at VHIO. Originally trained as a computer scientist, he transitioned to cancer genomics and epigenetics during his postdoctoral research at the Christina Curtis lab at Stanford University. In 2021, after securing a Ramon y Cajal grant, he establish his laboratory at VHIO. The primary focus of the lab is to identify biomarkers of drug response in solid tumors, elucidate the role of epigenetics in cancer initiation, progression and metastasis, and investigate the potential of chromatin machinery genes as therapeutic targets, using computational tools.
Abstract: Many genomic signatures have been developed, but most of them never arrive to the clinic. Out hypothesis is that most of the signatures developed are actually giving the same message. Here we developed a transcriptomic based signature for colon cancer prognosis. Out signature is able to match other colorectal prognostic signatures, and on top on that, is able to predict response to a specific chemotherapy. We have validated our signature in in-silico cell line response databases, and also in colorectal patient derived organoids.